Multiple Myeloma Treatment

Oct 04, 2024

Trispecific antibodies are the next frontier in targeted cancer therapy, offering a powerful new approach to treating complex diseases. These innovative antibodies are designed to bind to three different antigens simultaneously, enhancing treatment precision. By engaging multiple targets at once, trispecific antibo...

Sep 24, 2024

The landscape of multiple myeloma therapies has been revolutionized by the introduction of cutting-edge monoclonal antibodies (mAbs) targeting CD38. Among the standout advancements are DARZALEX (daratumumab) and SARCLISA (isatuximab-irfc), which have emerged as game-changers in the treatment of multiple myeloma. Th...

Aug 05, 2024

Despite significant progress in multiple myeloma treatment with a range of biological drugs and their combinations—such as IMiDs (BMS REVLIMID, POMALYST/IMNOVID), anti-CD38 monoclonal antibody drugs (DARZALEX, SARCLISA), the anti-SLAM7 monoclonal antibody (AbbVie and BMS multiple myeloma drug EMPLICITI), and new pr...

Jul 25, 2024

Over the years, REVLIMID has become an integral weapon in the cancer therapeutics armory. This odyssey of REVLIMID in the multiple myeloma segment began in 2005, when it was approved by the US FDA for the treatment of adult patients with multiple myeloma, in combination with dexamethasone.  As the wise say,...

Jul 24, 2024

Multiple myeloma is the second most prevalent blood cancer diagnosis in the United States, after non-Hodgkin lymphoma. Males are significantly more likely than females to have multiple myeloma. Myeloma incidence is strongly correlated with age, with the highest rates of diagnosis occurring in adults aged 65 years a...

Jul 24, 2024

Step aside, CAR-Ts; with three FDA approvals, the class of bispecific antibodies has begun to take on the relapsed/refractory multiple myeloma treatment segment. Currently, the FDA has authorized 10 bispecific antibodies and one bispecific molecule, the majority of which are approved for oncology indications, ...

Jul 23, 2024

Smoldering Multiple Myeloma (SMM) is an asymptomatic condition that acts as an intermediate stage between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. First described by Kyle and Greipp in 1980, SMM typically affects individuals aged 50 to 70 and is usually diagnosed incidentally ...

Nov 08, 2022

Amgen Reports Promising Mid-stage Results for its Olpasiran Candidate  Amgen has reported encouraging mid-stage results for its olpasiran candidate for lowering lipoprotein(a) - a risk factor for atherosclerotic cardiovascular disease - and now plans to move forward with a phase III program as soon as possi...